3-(RS)-氨基-1,3-二氢-1-甲基-5-(吡啶-2-基)-2H-1,4-苯并二氮杂-2-酮 | 136162-67-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯二氮卓类
• 中文名称: 3-(RS)-氨基-1,3-二氢-1-甲基-5-(吡啶-2-基)-2H-1,4-苯并二氮杂-2-酮
• 英文名称: 3-(RS)-amino-1,3-dihydro-1-methyl-5-(pyridin-2-yl)-2H-1,4-benzodiazepin-2-one
• 英文别名: 3-amino-2,3-dihydro-1-methyl-5-(pyridin-2-yl)-1H-1,4-benzodiazepin-2-one；3-amino-1-methyl-5-(pyridin-2-yl)-2,3-dihydro-1H-1,4-benzodiazepine-2-one；3-(RS)-amino-1,3-dihydro-1-methyl-5-(2-pyridyl)-2H-1,4-benzodiazepin-2-one；3-Amino-1-methyl-5-pyridin-2-yl-1,3-dihydro-benzo[e][1,4]diazepin-2-one；1,3-dihydro-1-methyl-3-amino-5-(pyrid-2-yl)-2H-1,4-benzodiazepine-2-one；3-amino-2,3-dihydro-1-methyl-5-(2-pyridyl)-1H-1,4-benzodiazepin-2-one；3-amino-1-methyl-5-pyridin-2-yl-3H-1,4-benzodiazepin-2-one
• CAS: 136162-67-9
• 化学式: C₁₅H₁₄N₄O
• 分子量: 266.302
• InChiKey: ZDPUKMGCAGDUCH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  71.6
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(RS)-氨基-1,3-二氢-1-甲基-5-(吡啶-2-基)-2H-1,4-苯并二氮杂-2-酮 以50%的产率得到[3-Methyl-1-(1-methyl-2-oxo-5-pyridin-2-yl-2,3-dihydro-1H-benzo[e][1,4]diazepin-3-ylcarbamoyl)-butyl]-carbamic Acid tert-Butyl Ester
  参考文献：
  名称：

  Amino lactam sulfonamides as inhibitors of A&bgr; protein production

  摘要：

  本发明涉及具有式（I）的新型内酰胺，其药物组成物和使用方法。这些新化合物抑制淀粉样前体蛋白的加工，更具体地抑制Aβ-肽的产生，从而防止神经沉积物的淀粉样蛋白质形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经系统疾病的治疗，例如阿尔茨海默病和唐氏综合症。

  公开号：

  US06503901B1
• 作为产物：
  描述：

  (RS)-3-<(benzyloxycarbonyl)amino>-2,3-dihydro-5-(2-pyridyl)-1H-1,4-benzodiazepin-2-one 在 氢溴酸 、 sodium hydride 、 溶剂黄146 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 生成 3-(RS)-氨基-1,3-二氢-1-甲基-5-(吡啶-2-基)-2H-1,4-苯并二氮杂-2-酮
  参考文献：
  名称：

  开发1,4-苯并二氮杂类胆囊收缩素B型拮抗剂。

  摘要：

  描述了一系列3-（芳基脲基）-5-苯基-1,4-苯并二氮杂卓，肽激素胆囊收缩素（CCK）的非肽拮抗剂。通过对CCK-A选择性3-甲酰胺基-1,4-苯并二氮杂卓MK-329的合理修饰而衍生，本文记载了有效的，口服有效的化合物的开发，其中对CCK-B受体亚型具有选择性。从这些研究中得出的主要铅结构是L-365,260，该化合物已提交临床评估。讨论了通过适当的结构修饰来调节这些苯并二氮杂the的受体相互作用的能力的细节，这暗示了进一步完善这类化合物的CCK-B受体亲和力和选择性的可能性。

  DOI：

  10.1021/jm00078a018

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Succinoylaminobenzodiazepines as inhibitors of Abeta protein production
  申请人：Olson E. Richard

  公开号：US20060025407A1

  公开（公告）日：2006-02-02

  This invention relates to novel lactams having the formula (I): to their pharmaceutical compositions and to their methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of Aβ-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to β-amyloid production such as Alzheimer's disease and Down's Syndrome.

  这项发明涉及具有以下结构式（I）的新型内酰胺，以及它们的药物组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地说，抑制Aβ肽的产生，从而防止神经沉积物的淀粉样蛋白形成。更具体地，本发明涉及与β-淀粉样蛋白产生相关的神经疾病的治疗，如阿尔茨海默病和唐氏综合征。
• Benzodiazepine analogs for treating panic syndrome and for directly inducing analgesia
  申请人：MERCK & CO. INC.

  公开号：EP0434364A3

  公开（公告）日：1992-04-01

  Benzodiazepine analogs of the formula: are disclosed which are antagonists of gastrin and cholecystokinin (CCK) and have properties useful for treating panic syndrome and for directly inducing analgesia.

  公开了以下化学式的苯二氮䓬类似物：这些类似物是胃泌素和胆囊收缩素（CCK）的拮抗剂，并具有用于治疗惊恐综合症和直接诱导镇痛的特性。
• Substituted lactams as inhibitors of A beta protein production
  申请人：——

  公开号：US20020025955A1

  公开（公告）日：2002-02-28

  This invention relates to novel lactams of Formula (I): 1 having drug and bio-affecting properties, their pharmaceutical compositions and methods of use. These novel compounds inhibit the processing of amyloid precursor protein and, more specifically, inhibit the production of A&bgr;-peptide, thereby acting to prevent the formation of neurological deposits of amyloid protein. More particularly, the present invention relates to the treatment of neurological disorders related to &bgr;-amyloid production such as Alzheimer's disease and Down's Syndrome.

  本发明涉及具有药物和生物影响性质的新型内酰胺化合物（I）的公式，以及它们的制药组合物和使用方法。这些新型化合物抑制淀粉样前体蛋白的加工，更具体地抑制A&bgr;-肽的产生，从而防止淀粉样蛋白质的神经沉积形成。更具体地，本发明涉及与&bgr;-淀粉样蛋白产生相关的神经疾病的治疗，例如阿尔茨海默病和唐氏综合症。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。